89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Our culture is best described by our values:
•	Always putting the patient first
•	Operating with the highest integrity and ethical standards at all times
•	Being authentic in all our transactions
•	Acting as a team – collaborating, respecting and caring for one another
•	Being entrepreneurial and passionate in our tasks
•	Being scientific and rational in our thought process and decision-making


K2 HealthVentures

Longitude Capital

OrbiMed

Pontifax

RA Capital Management

89bio

It’s #NationalTriglycerides day: do you know your numbers? Our #triglyceride levels play a key role in living a healthy lifestyle. Elevated triglyceride levels can increase the risk of several conditions, including #CardiovascularDisease and #MetabolicSyndrome.
 
Learn more about Severe Hypertriglyceridemia or #SHTG and 89bio’s mission to develop treatment options: https://lnkd.in/gE7AwYWu

Our investigational FGF21 analog has received the European Medicines Agency Priority Medicines (PRIME) status in patients with non-cirrhotic #MASH with fibrosis and MASH with compensated cirrhosis. This designation was supported by the positive data from our Phase 2b ENLIVEN trial. 

Learn more about the PRIME status and what this means for us: https://lnkd.in/gSDeAeAK

#NASH #MASH #Innovation #the89way
 


We’re excited to announce the initiation of our Phase 3 ENLIGHTEN-Fibrosis trial, which will evaluate the efficacy and safety of our investigational fibroblast growth factor 21 (FGF21) analog in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. This new phase marks an inspiring milestone in our progress toward developing meaningful medicines. 

To learn more, read our release: https://lnkd.in/eG6UuC-P 
 
#NASH #MASH #ClinicalTrials #Innovation

Join our growing team at 89bio! Our team of experts embrace a start-up mindset, cultivate an entrepreneurial spirit and are driven to create the best opportunities for our hard-working team of 89ers. If this sounds like you, and you’re passionate about developing innovative therapies for #CardioMetabolic diseases, check out our open roles and learn more about #the89way: https://lnkd.in/gnP5i8-n

#HealthcareJobs #Hiring

Galmed Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutics for liver diseases, including NASH and SHTG.

Galmed Pharmaceuticals

Inventiva Pharma is a clinical-stage biopharmaceutical company specializing in the development of therapies for fibrotic diseases, including NASH.

Inventiva Pharma

Madrigal Pharmaceuticals is dedicated to the development of innovative therapies for cardiovascular and metabolic diseases, including NASH and SHTG.

Madrigal Pharmaceuticals

89Bio is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is BIO89-100, which is being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 8:24 AM	e6835a6d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	4e36f1b6
crunchbase profile	general
li profile	general	May 14, 2024 8:24 AM	171a7465
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:89BIO

89Bio

Last Close

8.38

22/11 21:00

Market Cap

851.02M

Beta: -

Volume Today

477.49K

Avg: -